Hubei Jumpcan Pharmaceutical Co., Ltd. (600566) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hubei Jumpcan Pharmaceutical Co., Ltd.

Why is Hubei Jumpcan Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 2.31% and Operating profit at 4.74% over the last 5 years

With a fall in Net Sales of -19.99%, the company declared Very Negative results in Mar 25

The company has declared negative results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Lowest at CNY 1,729.36 MM
ROCE(HY) Lowest at 14.5%
DEBTORS TURNOVER RATIO(HY) Lowest at 3.9%

Underperformed the market in the last 1 year

Even though the market (China Shanghai Composite) has generated returns of 14.77% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -7.71% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Hubei Jumpcan Pharmaceutical Co., Ltd. for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

Hubei Jumpcan Pharmaceutical Co., Ltd.

-100.0%

-1.27

23.20%

China Shanghai Composite

15.19%

1.01

14.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

2.31%

EBIT Growth (5y)

4.74%

EBIT to Interest (avg)

81.87

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

0.59

Tax Ratio

14.86%

Dividend Payout Ratio

75.53%

Pledged Shares

Institutional Holding

ROCE (avg)

56.77%

ROE (avg)

17.31%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.71

EV to EBIT

7.05

EV to EBITDA

6.05

EV to Capital Employed

3.63

EV to Sales

2.02

PEG Ratio

Dividend Yield

8.32%

ROCE (Latest)

51.43%

ROE (Latest)

14.13%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

CASH AND EQV(HY)

Highest at CNY 24,413.7 MM

DEBT-EQUITY RATIO (HY)

Lowest at -76.15 %

-31What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 1,729.36 MM

ROCE(HY)

Lowest at 14.5%

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.9%

NET SALES(Q)

Lowest at CNY 1,497.04 MM

OPERATING PROFIT(Q)

Lowest at CNY 426.85 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 28.51 %

PRE-TAX PROFIT(Q)

Lowest at CNY 502.7 MM

NET PROFIT(Q)

Lowest at CNY 430.07 MM

EPS(Q)

Lowest at CNY 0.48

Here's what is working for Hubei Jumpcan Pharmaceutical Co., Ltd.

Cash and Eqv

Highest at CNY 24,413.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -76.15 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Hubei Jumpcan Pharmaceutical Co., Ltd.

Net Sales

At CNY 1,497.04 MM has Fallen at -24.03%

over average net sales of the previous four periods of CNY 1,970.63 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY 1,729.36 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Lowest at CNY 1,497.04 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 426.85 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 28.51 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 502.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

At CNY 502.7 MM has Fallen at -30.16%

over average net sales of the previous four periods of CNY 719.76 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 430.07 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Net Profit

At CNY 430.07 MM has Fallen at -29.7%

over average net sales of the previous four periods of CNY 611.75 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.48

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debtors Turnover Ratio

Lowest at 3.9%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio